

Available online at www.sciencedirect.com



Bioorganic & Medicinal Chemistry Letters

Bioorganic & Medicinal Chemistry Letters 15 (2005) 2011-2014

Semi-synthesis and biological evaluation of analogues of UK-2A, a novel antifungal antibiotic from *Streptomyces* sp. 517-02

Yoshinosuke Usuki,^{a,*} Koichi Mitomo,^c Noriko Adachi,^a Xu Ping,^b Ken-Ichi Fujita,^b Osamu Sakanaka,^c Katsuharu Iinuma,^d Hideo Iio^a and Makoto Taniguchi^{b,*}

^aDepartment of Material Science, Graduate School of Science, Osaka City University, 3-3-138 Sugimoto, Sumiyoshi-ku, Osaka 558-8585, Japan

^bDepartment of Biology, Graduate School of Science, Osaka City University, 3-3-138 Sugimoto, Sumiyoshi-ku, Osaka 558-8585, Japan ^cCMC Research Laboratories, Meiji Seika Kaisha Ltd, Kayama, Odawara-shi, Kanagawa 250-0852, Japan ^dFuji Amide Chemical Co., Ltd, Ukima, Kita-ward, Tokyo 115-0051, Japan

Received 17 January 2005; revised 17 February 2005; accepted 19 February 2005

Abstract—Several analogues of UK-2A, a novel antifungal antibiotic isolated from *Streptomyces* sp. 517-02, were semi-synthesized for structure–activity studies. In vitro antifungal activities of these compounds against *Saccharomyces cerevisiae* IFO 0203 were evaluated by the conventional paper disk method. Several derivatives exhibited growth inhibitory activity similar to UK-2A. © 2005 Elsevier Ltd. All rights reserved.

UK-2A is an antifungal antibiotic produced by *Streptomyces* sp. 517-02, and is similar to antimycin A_3 (AA) in both structure and inhibitory activity toward electron transport at complex III in mitochondria.¹⁻⁴ Both UK-2A and AA consist of nine-membered dilactone rings linked via an amide bond to an aromatic acid moiety (Fig. 1): UK-2A possesses a 3-hydroxy-4-methoxypicolinic moiety, while the AAs have 3-formamidosalicylic moieties, reported to be essential for binding to complex III protein and the inhibition of electron transfer between cytochromes b and c_1 in the mitochondrial respiratory chain.⁵ The benzyl group at the C2 position in UK-2A has not been reported in antimycins and a methyl group is lacking at the C8 position. Furthermore, UK-2A was less cytotoxic than AA against several mammalian cell lines, including murine leukemia P388, murine melanoma B16, porcine renal proximal tubule LLC-PK₁, human oral epidermoid carcinoma KB, and human colon adenocarcinoma COLO201.⁶ As both UK-2A and AA inhibited mitochondrial electron transport, the difference in cytotoxicity between UK-2A and





Figure 1. The structures of UK-2A and AA, showing the focus of SAR.

AA could be attributed to their ability to produce reactive oxygen species.^{6,7} In continuing studies on UK-2A,⁸ we have been interested in establishing structure–activity relations among UK-2A analogues.^{9–11} This study focuses on (1) the 3'-OH group, (2) the benzene moiety, and (3) selective cleavage of the amide bond as shown in Figure 1, and reports the results of preliminary studies on the semi-synthetic preparation and biological evaluation of UK-2A analogues.

Keywords: Antifungal activity; Respiratory inhibition; Structureactivity relationship; Nine-membered dilactone; UK-2A.

^{*} Corresponding authors. Tel.: +81 6 6605 2563; fax: +81 6 6605 2522 (Y.U.); e-mail addresses: usuki@sci.osaka-cu.ac.jp; makoto@sci. osaka-cu.ac.jp

⁰⁹⁶⁰⁻⁸⁹⁴X/\$ - see front matter @ 2005 Elsevier Ltd. All rights reserved. doi:10.1016/j.bmcl.2005.02.065




Scheme 1. Alkylation and acylation of the 3'-OH group of UK-2A.

To examine the role of the 3'-OH group in analogue activity, the chemically modified analogues 3-7 were prepared as shown in Scheme 1. Treatment of UK-2A with iodomethane and ethyl bromoacetate under alkaline conditions afforded the corresponding 3'-O-alkylated compounds 3 and 4, respectively, in modest yields. Acylation of UK-2A with acetic anhydride and pyridine proceeded smoothly to afford compound 5 in quantitative yield. Heptanedioyl dichloride was treated with an equimolar amount of benzyl alcohol and triethyl amine in dichloromethane; addition of a UK-2A solution in dichloromethane afforded the corresponding diester derivative 6 in 62% yield. Hydrogenation of 6 over Pd/C in MeOH gave monoacid 7 in 66% yield.


Then we were interested in introducing nitrogen functionality into the benzene moiety of UK-2A (Scheme 2). Treatment of UK-2A with fumic HNO₃ in dichloromethane at -20 °C achieved *para*-selective nitration of the benzene ring in good yield. Compound **8** thus obtained was hydrogenated over Pd/C in EtOH to give amine 9 in 72% yield. Treatment of 9 with Ac₂O and formic acid in dichloromethane afforded *N*-formated 10. In the presence of aqueous HCHO, 9 was hydrogenated over Pd/C in EtOH to give N,N-dimethyl amine 11 in 66% yield.

The chemo-selective amide bond cleavage of UK-2A was expected to afford the nine-membered dilactone amine **B**, which is a useful building block for UK-2A derivatives. However, the acidic or basic hydrolysis of amide bonds requires prolonged heating that could decompose UK-2A. A survey of mild hydrolysis reagents led to the choice of phosphorus pentachloride (PCl₅), which has been applied to the removal of amide side chains in the industrial scale manufacture of semi-synthetic cephalosporins¹² and penicillins.¹³

Treatment of 3'-O-acetylated UK-2A (5) with PCl₅-pyridine (2 equiv of each) in dichloromethane, followed by



Scheme 2. Introduction of nitrogen functionality of the benzene ring of UK-2A.



Scheme 3. Chemo-selective cleavage of the amide bond and condensation with o-hydroxyl aromatic acids.

heating under reflux for 1.5 h, afforded the imidoyl chloride intermediate, which was then converted to the imino ether with MeOH. Further aqueous work-up gave **B** as a *p*-toluenesulfonic acid salt in 51% yield along with methyl picolinate derivative **A** in 21% yield. Amide formation of **B** with various *o*-hydroxyl aromatic acids was achieved in THF–pyridine with EDC·HCl and HOBt in modest to good yields. The structures of UK-2A derivatives (**12–17**) prepared according to this method are presented in Scheme 3.

Compounds 3–17¹⁴ were then evaluated for in vitro antifungal activity against *Saccharomyces cerevisiae* IFO 0203 by the conventional paper disk method using a test medium composed of 1% yeast extract, 2% polypeptone, 3% glycerol, and 2% Bacto-agar. Results are summarized in Table 1.

O-Alkylation products (3 and 4) did not inhibit the growth of S. cerevisiae, while the O-acylated derivatives 5–7 showed inhibitory activity less than that exhibited by UK-2A, suggesting that in vivo hydrolysis of 5-7 regenerates UK-2A, and the carboxylic group in 7 facilitated smooth reaction. The ether bonds in 3 and 4 are chemically and enzymatically stable and may prevent the regeneration of UK-2A in vivo. The free 3'-OH group is thus essential for the growth inhibitory activity as reported earlier for AA.⁵ Among derivatives with a substituent at the *para* position of the benzene ring (8– 11), the *p*-nitro derivative 8 showed the strongest inhibitory activity; no relation between the electronegativity or basicity of substituents and growth inhibition was found. The replacement of a picolinic acid moiety by salicylic acid derivatives resulted in a slight decrease in the inhibition. 3-Hydroxy-2-quinoxalinecarboxylic acid derivative 12 and 3-hydroxy-6-methoxypicolinic acid derivative 13 showed inhibitory activity similar to

UK-2A, suggesting that substitutions at the 5'- and/or 6'-position of picolinic acid are not effective promoters of growth inhibitory activity.

In summary, chemical modifications of the 3'-OH group revealed that the free hydroxyl group at the 3' position is necessary for the inhibitory activity in UK-2A as well as AAs. Nitration at the *para* position of the benzene moiety and chemo-selective cleavage of the amide bond were achieved in good yields without decomposition of the nine-membered dilactone ring of UK-2A. *p*-Amino derivative **9** is a suitable precursor for photoaffinity-labeled

Table 1. Antifungal activity of UK-2A, AA, and their derivatives $(3-17)^a$

Compounds	Dose (µg/disc)			
	0.025	0.05	0.125	0.25
UK-2A (1)	19	22	26	26
AA (2)	16	18	19	26
3	0	0	0	0
4	0	0	0	0
5	10	12	14	18
6	8	10	15	18
7	12	16	21	24
8	12	15	18	20
9	0	0	8	10
10	0	0	0	0
11	0	11	15	19
12	14	18	20	24
13	16	19	24	27
14	0	12	16	17
15	8	8	11	12
16	8	12	16	17
17	8	8	12	14

^a Values are stated in diameter of inhibitory zone around the discs (mm).

analogues designed for elucidating the UK-2A binding site on mitochondria.

Acknowledgements

This research was partially supported by Grant-in-Aids for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (nos. 12556017 and 14580615), which are gratefully appreciated.

References and notes

- 1. Ueki, M.; Abe, K.; Hanafi, M.; Shibata, K.; Tanaka, T.; Taniguchi, M. J. Antibiot. **1996**, 49, 639.
- Hanafi, M.; Shibata, K.; Ueki, M.; Taniguchi, M. J. Antibiot. 1996, 49, 1226.
- 3. Ueki, M.; Taniguchi, M. J. Antibiot. 1997, 50, 1052.

- Shibata, K.; Hanafi, M.; Fujii, J.; Sakanaka, O.; Iinuma, M.; Ueki, M.; Taniguchi, M. J. Antibiot. 1998, 51, 1113.
- 5. Tokutake, N.; Miyoshi, H.; Satoh, T.; Hatano, T.; Iwamura, H. Biochim. Biophys. Acta 1994, 1185, 271.
- 6. Takimoto, H.; Akimoto, H.; Machida, K.; Ueki, M.; Tanaka, T.; Taniguchi, M. J. Antibiot. **1999**, *52*, 480.
- Machida, K.; Takimoto, H.; Miyoshi, H.; Taniguchi, M. J. Antibiot. 1999, 52, 748.
- 8. For a review, see: Ueki, M.; Machida, K.; Taniguchi, M. *Curr. Opin. Anti-infective Invest. Drugs* **2000**, *2*, 387.
- 9. Usuki, Y.; Tani, K.; Fujita, K.-I.; Taniguchi, M. J. Antibiot. 2001, 54, 600.
- Usuki, Y.; Goto, K.; Kiso, T.; Tani, K.; Ping, X.; Fujita, K.-I.; Taniguchi, M. J. Antibiot. 2002, 55, 607.
- Fujita, K.-I.; Kiso, T.; Usuki, Y.; Tanaka, T.; Taniguchi, M. J. Antibiot. 2004, 57, 687.
- 12. Fechtig, B.; Peter, H.; Bickel, H.; Vischer, E. Helv. Chim. Acta 1968, 51, 1108.
- Weissenburger, H. W. O.; van der Hoeven, M. G. Recl. Trav. Chim. Pays-Bas 1970, 89, 1081.
- 14. The identity and purity of all new compounds were established by ¹H NMR and MS.